AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 56 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,649 | +182350.0% | 8,091 | +115485.7% | 0.00% | – |
| Q1 2023 | $2 | -50.0% | 7 | -12.5% | 0.00% | – |
| Q4 2022 | $4 | -100.0% | 8 | -100.0% | 0.00% | – |
| Q2 2022 | $39,000 | -74.0% | 76,806 | +17.7% | 0.00% | – |
| Q1 2022 | $150,000 | -76.9% | 65,276 | -52.2% | 0.00% | – |
| Q4 2021 | $649,000 | +50.6% | 136,636 | +152.0% | 0.00% | – |
| Q3 2021 | $431,000 | +19.1% | 54,220 | +4.1% | 0.00% | – |
| Q2 2021 | $362,000 | -8.6% | 52,077 | +4.2% | 0.00% | – |
| Q1 2021 | $396,000 | +10.9% | 49,973 | +10.2% | 0.00% | – |
| Q4 2020 | $357,000 | +35.2% | 45,360 | +21.7% | 0.00% | – |
| Q3 2020 | $264,000 | -34.5% | 37,285 | -14.4% | 0.00% | – |
| Q2 2020 | $403,000 | +96.6% | 43,569 | -1.1% | 0.00% | – |
| Q1 2020 | $205,000 | -51.2% | 44,036 | -19.9% | 0.00% | – |
| Q4 2019 | $420,000 | -6.9% | 55,003 | -6.2% | 0.00% | – |
| Q3 2019 | $451,000 | +53.9% | 58,669 | +37.2% | 0.00% | – |
| Q2 2019 | $293,000 | -13.6% | 42,760 | +1.6% | 0.00% | – |
| Q1 2019 | $339,000 | +6.3% | 42,097 | -1.2% | 0.00% | – |
| Q4 2018 | $319,000 | -37.3% | 42,626 | -19.8% | 0.00% | – |
| Q3 2018 | $509,000 | -35.1% | 53,170 | -28.2% | 0.00% | – |
| Q2 2018 | $784,000 | +221.3% | 74,015 | +201.3% | 0.00% | – |
| Q1 2018 | $244,000 | +3385.7% | 24,565 | +1752.6% | 0.00% | – |
| Q4 2017 | $7,000 | -30.0% | 1,326 | -32.1% | 0.00% | – |
| Q3 2017 | $10,000 | 0.0% | 1,954 | -25.1% | 0.00% | – |
| Q2 2017 | $10,000 | +42.9% | 2,608 | +164.2% | 0.00% | – |
| Q1 2017 | $7,000 | +133.3% | 987 | +23.4% | 0.00% | – |
| Q4 2016 | $3,000 | -97.3% | 800 | -95.4% | 0.00% | – |
| Q3 2016 | $112,000 | +220.0% | 17,371 | +141.3% | 0.00% | – |
| Q2 2016 | $35,000 | – | 7,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $258,000 | 3.49% |
| Aisling Capital Management LP | 1,691,151 | $3,890,000 | 2.10% |
| Sio Capital Management, LLC | 871,101 | $2,004,000 | 0.66% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $6,550,000 | 0.64% |
| Samsara BioCapital, LLC | 883,720 | $2,033,000 | 0.51% |
| Ghost Tree Capital, LLC | 686,599 | $1,579,000 | 0.34% |
| Nantahala Capital Management | 3,200,593 | $7,361,000 | 0.33% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $565,000 | 0.29% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4,059,894 | $9,338,000 | 0.28% |
| Lion Point Capital, LP | 300,000 | $690,000 | 0.16% |